Published in Law and Health Weekly, March 31st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Roche.
Report 1: An interim analysis of a phase III study in advanced renal cell cancer has shown that Avastin significantly prolongs the time patients live without their disease progressing.
In addition, this early analysis indicated a trend towards an improvement in overall survival. Renal cell cancer is the most common form of kidney cancer, accounting for 9 out of 10 cases, and treatment options are limited. Due to the benefits observed, the independent Drug Safety Monitoring...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.